Search

Your search keyword '"Ibayashi J"' showing total 2 results
Start Over Author "Ibayashi J" Journal gan to kagaku ryoho cancer chemotherapy
2 results on '"Ibayashi J"'

1. [Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].

Author

Sasaki T, Ota K, Ibayashi J, Sakata Y, Matsuoka T, Ishikawa M, Wakui A, Ogoshi K, Akazawa S, and Sakai Y

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials as Topic, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Japan, Leucovorin administration & dosage, Leucovorin adverse effects, Leukopenia chemically induced, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Multicenter Studies as Topic, Nausea chemically induced, Prospective Studies, Quality of Life, Random Allocation, Remission Induction, Stomach Neoplasms rehabilitation, Vomiting chemically induced, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Fluorouracil therapeutic use, Stomach Neoplasms drug therapy
Abstract

In a recent phase II trial we have shown a favorable response rate for sequential methotrexate-5-fluorouracil (MF) in advanced gastric and colorectal cancer. We determined the therapeutic effect of sequential MF in patients with advanced gastric cancer by comparing it to 5-fluorouracil alone (F) in a randomized multicenter trial. Since February 1987 to July 1988, 133 patients with advanced gastric cancer have been prospectively randomized to receive either MF (methotrexate 100 mg/m2 i.v. push, 5-fluorouracil 600 mg/m2 i.v. drip over 15 minutes one hour after methotrexate and leucovorin 15 mg p.o. q 6 hrs x 2 beginning 24 hrs after methotrexate) of F (the same 5-fluorouracil as described for MF). Each treatment was repeated weekly x 5, then q 2 weeks. The two treatment arms were balanced for 17 clinical characteristics. The response rate was 17.9% (10 of 56 patients) in the MF arm and 1.9% (one of 53 patients) in the F arm (p less than 0.01). Median duration of response was 6.8 weeks (MF) and 6 weeks (F), respectively. Median survival time was 7.9 months (MF) and 7.3 months (F) on interim findings. Leukocytopenia and GI toxicity were significantly more common in patients receiving MF, but the degree was similar for both arms. Other side effects were minimal and no different. This schedule of MF is more effective than F in inducing remission for patients with advanced gastric cancer.

Published
1989

2. [Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].

Author

Ibayashi J

Subjects
Administration, Oral, Adult, Aged, Colonic Neoplasms drug therapy, Delayed-Action Preparations, Drug Evaluation, Esophageal Neoplasms drug therapy, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms drug therapy, Stomach Neoplasms drug therapy, Tegafur administration & dosage, Digestive System Neoplasms drug therapy, Fluorouracil analogs & derivatives, Tegafur therapeutic use
Abstract

A Phase II Study of single oral administration of SF-SP containing sustained-release granules of tegafur was conducted in 37 cases of advanced cancers by 9 institutions in the Hokkaido area. Two capsules each containing 200 or 250 mg of SF-SP were orally administered twice daily for a total of either 800 or 1000 mg per day. The results were as follows: Of the 24 evaluable cases PR was observed in 4 cases. (16.7%) The observed efficacy rate by cancer type was 23.5% for gastric cancer and toxicity was observed in 10 (27.8%) of 35 subject cases. These results thus indicate SF-SP to be therapeutically effective for treatment of gastric cancers, with mild toxicity.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results